Builds on positive Phase I safety data and represents a key value-inflection milestone for the Company Advances a potentially disease-modifying approach for fragile X syndrome, a condition with no approved targeted therapies Barcelona, Spain – 10 June 2026 – CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class...
Continue readingCTH120 is a first-in-class neuroplasticity modulator with strong Phase I safety and tolerability data Awarded a €2.5M European Innovation Council (EIC) Accelerator grant to prepare for Phase II development in pediatric Fragile X Syndrome (FXS) patients CONNECTA leads innovation in neurodevelopmental therapies as a unique European biotech...
Continue readingCONNECTA Therapeutics has announced positive results from its Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics profile of its drug candidate CTH120 in adult volunteers. CTH120 is an investigational drug that modulates neuroplasticity, a property of the brain affected in many neurodevelopmental disorders,...
Continue readingThe European Innovation Council (EIC) announced yesterday that CONNECTA Therapeutics has been selected for grant and equity funding, following the last EIC Accelerator cut-off. CONNECTA Therapeutics is honored to be part of the 71 European companies selected among 1211 submitted proposals in the most competitive funding round so...
Continue readingThe Phase IIa study will assess the efficacy of CTH120 as an innovative therapy in adults with FXS, the most common form of inherited intellectual disability without a specific treatment. María Martínez, Jordi Fàbrega, Mara Dierssen, Ana Aldea, Rafael de la Torre and Ana Roche representing CONNECTA...
Continue readingHospital del Mar Research Institute CONNECTA Therapeutics announces that the first healthy volunteers in the Phase I clinical trial of CTH120 have been administered the drug at Hospital del Mar - Hospital del Mar Research Institute in Barcelona. The study is recruiting 68 healthy individuals, both women and men aged between 18 and 55 years,...
Continue readingThis Phase I clinical trial will assess the safety and tolerability of CTH120, which acts as a neuroplasticity modulator. CTH120 has shown very promising results in preclinical studies carried out at Dr Mara Dierssen research lab at the Centre for Genomic Regulation in Barcelona. The study will...
Continue readingConnecta Therapeutics, a biotechnology company that specialises in the discovery and development of new treatments for unmet central nervous system (CNS) needs, has been granted €247,577 in funding through the Neotec programme, managed by the Spanish Ministry of Science and Innovation Centre for the Development...
Continue readingBarcelona, 06 September 2021 CTH120, designed using artificial intelligence techniques, will start Phase I in 2022 CTH120 designation as orphan drug validates and empowers Connecta Therapeutics's strategy in neurodevelopmental diseases CTH120 Connecta Therapeutics has received approval as orphan drug from the European Medicines Agency (EMA) to treat fragile...
Continue readingBarcelona The public-private consortium has obtained a grant of €1.97 million from the Spanish National Innovation Agency Preclinical studies have shown that the CTH120 molecule can modulate neuroplasticity, the ability of cells of the nervous system to regenerate in response to pathological influences The public-private consortium formed by...
Continue reading